15 results on '"Ohsawa, Masahiro"'
Search Results
2. Effect of naloxone on ischemic acute kidney injury in the mouse.
- Author
-
Mutoh, Junpei, Ohsawa, Masahiro, and Hisa, Hiroaki
- Subjects
- *
NALOXONE , *ISCHEMIA , *KIDNEY injuries , *LABORATORY mice , *OPIOID receptors , *BLOOD urea nitrogen , *TYROSINE hydroxylase , *THERAPEUTICS - Abstract
Abstract: Renal ischemia produces sympathoexcitation, which is responsible for the development of ischemic acute kidney injury. Stimulation of central opioid receptors activates the renal sympathetic nerve. The present study examined the effect of an opioid receptor antagonist naloxone on the ischemia/reperfusion-induced renal dysfunction in mice. Blood urea nitrogen (BUN) and plasma creatinine increased 24 h after the renal ischemia/reperfusion. Intraperitoneal or intracerebroventricular, but not intrathecal, pretreatment with naloxone suppressed the renal ischemia/reperfusion-induced increases in BUN and plasma creatinine. This effect of naloxone was reversed by subcutaneous pretreatment with morphine. Selective MOP receptor antagonist β-funaltrexamine (FNA) also suppressed the renal ischemia/reperfusion-induced increases in BUN and plasma creatinine. Moreover, tyrosine hydroxylase expression in the renal tissue increased 24 h after renal ischemia/reperfusion, which was abolished by intraperitoneal or intracerebroventricular pretreatment with naloxone and FNA. Immunohistochemical experiments revealed a significant increase in the number of the Fos family proteins (c-Fos, FosB, Fra-1, and Fra-2) positive cells in the paraventricular nucleus of hypothalamus and supraoptic nucleus 24 h after the renal ischemia/reperfusion. Intracerebroventricular pretreatment with naloxone attenuated the renal ischemia/reperfusion-induced increase in the number of the Fos family proteins positive cells in these areas. Finally, we observed that i.c.v. pretreatment with antiserum against β-endorphin also suppressed the increased blood urea and plasma creatinine. These results suggest that the blockade of central opioid receptors can attenuate the ischemic acute kidney injury through the inhibition of renal sympathoexcitation. The central opioid receptors may thus be a new target for the treatment of ischemic organ failures. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
3. Reduction in Sympathetic Nerve Activity as a Possible Mechanism for the Hypothermic Effect of Oseltamivir, an Anti-influenza Virus Drug, in Normal Mice.
- Author
-
Ono, Hideki, Iwajima, Yui, Nagano, Yuko, Chazono, Kaori, Maeda, Yasuhiro, Ohsawa, Masahiro, and Yamamoto, Shohei
- Subjects
OSELTAMIVIR ,HYPOTHERMIA ,LABORATORY mice ,SYMPATHETIC nervous system ,ANTIPYRETICS ,ANTIVIRAL agents - Abstract
Oseltamivir, an anti-influenza virus drug, has strong antipyretic effects in mice ( Biological and Pharmaceutical Bulletin, 31, 2008, 638) and patients with influenza. In addition, hypothermia has been reported as an adverse event. The prodrug oseltamivir is converted to oseltamivir carboxylate ( OC), an active metabolite of influenza virus neuraminidase. In this study, core body temperature was measured in mice, and oseltamivir and OC were administered intracerebroventricularly (i.c.v.) or intraperitoneally (i.p). Low i.c.v. doses of oseltamivir and OC dose-dependently produced hypothermia. Zanamivir (i.c.v.), another neuraminidase inhibitor, did not produce hypothermia. These results suggested that the hypothermic effects of oseltamivir (i.p. and i.c.v.) and OC (i.c.v.) are not due to neuraminidase inhibition. OC (i.p.) did not lower body temperature. Although mecamylamine (i.c.v.) blocked the hypothermic effect of nicotine-administered i.c.v., the hypothermic effects of oseltamivir and OC (i.c.v.) were not blocked by mecamylamine (i.c.v.). The effect of oseltamivir (i.p.) was markedly increased by s.c.-pre-administered mecamylamine and also hexamethonium, a peripherally acting ganglionic blocker, suggesting their potentiating interaction at peripheral sites. The hypothermic effect of nicotine (i.c.v.) was decreased by lower doses of oseltamivir (i.c.v.), suggesting the anti-nicotinic action of oseltamivir. These results suggest that oseltamivir (i.p.) causes hypothermia through depression of sympathetic temperature regulatory mechanisms via inhibition of nicotinic receptor function and through unknown central mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Carnosine has antinociceptive properties in the inflammation-induced nociceptive response in mice
- Author
-
Ohsawa, Masahiro, Mutoh, Junpei, Asato, Megumi, Yamamoto, Shohei, Ono, Hideki, Hisa, Hiroaki, and Kamei, Junzo
- Subjects
- *
CARNOSINE , *ANALGESICS , *INFLAMMATION , *IMMUNOHISTOCHEMISTRY , *ASTROCYTES , *SPINAL cord , *DRUG administration , *LABORATORY mice - Abstract
Abstract: Carnosine is a biologically active dipeptide that is found in fish and chicken muscle. Recent studies have revealed that carnosine has neuroprotective activity in zinc-induced neural cell apoptosis and ischemic stroke. In the present study, we examined the expression of carnosine in the spinal cord, and the antinociceptive potency of carnosine in a mouse model of inflammation-induced nociceptive pain. Immunohistochemical studies with antiserum against carnosine showed an abundance of carnosine-immunoreactivity in the dorsal horn of the mouse spinal cord. Double-immunostaining techniques revealed that carnosine was expressed in the neurons and astrocytes in the spinal cord. Oral administration of carnosine attenuated the number of writhing behaviors induced by the intraperitoneal administration of 0.6% acetic acid. Treatment with carnosine also attenuated the second phase, but not the first phase, of the nociceptive response to formalin. Moreover, intrathecal, but not intraplanter, administration of carnosine attenuated the second phase of the nociceptive response to formalin. Our immunohistochemical and behavioral data suggest that carnosine has antinociceptive effects toward inflammatory pain, which may be mediated by the attenuation of nociceptive sensitization in the spinal cord. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
5. Chlorpheniramine exerts anxiolytic-like effects and activates prefrontal 5-HT systems in mice.
- Author
-
Miyata, Shigeo, Hirano, Shoko, Ohsawa, Masahiro, and Kamei, Junzo
- Subjects
AMINES ,TRANQUILIZING drugs ,LABORATORY mice ,THERAPEUTIC use of amino acids ,ANTIHISTAMINES ,PANIC attacks ,PHOBIAS treatment ,MENTAL health services ,AFFECTIVE disorders ,THERAPEUTICS - Abstract
Rationale: The traditional antihistamine chlorpheniramine ameliorates panic attacks, phobias, and lowered mood, and this therapeutic effect is independent of the blockade of histamine H receptors. Since chlorpheniramine inhibits the reuptake of serotonin (5-HT), the anxiolytic-like effect of chlorpheniramine may be produced by an increase in serotonergic function. Objective: To elucidate the mechanisms underlying the anxiolytic-like effects of chlorpheniramine in mice, we examined the involvement of 5-HT systems in the prefrontal cortex that is a crucial region in the regulation of emotional function. Results: Chlorpheniramine (0.05-5 mg/kg, i.p.) dose-dependently and significantly decreased the duration of freezing behavior in both the elevated open-platform and conditioned fear tests. The anti-freezing effects of chlorpheniramine (5 mg/kg, i.p.) in these tests were inhibited by pretreatment with the non-selective antagonist at 5-HT receptors, methiothepin (0.01 mg/kg, s.c.). In addition, the local injection of chlorpheniramine (10-100 ng/mouse) and 5-HT (1-10 μg/mouse) into the medial part of the prefrontal cortex (mPFC) dose-dependently and significantly decreased the duration of freezing behavior in the elevated open-platform test. In a microdialysis study, chlorpheniramine (0.5 and 5 mg/kg, i.p.) dose-dependently and significantly increased the extracellular 5-HT level in the mPFC. In addition, the local perfusion of chlorpheniramine (10 and 30 μM), but not of the selective H1 receptor antagonist, cetirizine, into the mPFC markedly increased the extracellular 5-HT level in the mPFC. Conclusion: The anxiolytic-like effect of chlorpheniramine is produced, at least in part, by the facilitation of serotonergic neurotransmission in the PFC. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
6. The effect of substance P1–7 amide on nociceptive threshold in diabetic mice
- Author
-
Ohsawa, Masahiro, Carlsson, Anna, Asato, Megumi, Koizumi, Takayuki, Nakanishi, Yuki, Fransson, Rebecca, Sandström, Anja, Hallberg, Mathias, Nyberg, Fred, and Kamei, Junzo
- Subjects
- *
SUBSTANCE P , *AMIDES , *HYPERALGESIA , *PEPTIDES , *SIGMA receptors , *OPIOID receptors , *LABORATORY mice , *ANIMAL models of diabetes - Abstract
Abstract: We previously demonstrated that intrathecal treatment with substance P metabolite substance P1–7 induced anti-hyperalgesia in diabetic mice. In the present study, we have used a synthetic analog of this peptide, the substance P1–7 amide, showing higher binding affinitiy than the native heptapeptide, for studies of the tail-flick response in diabetic and non-diabetic mice. Intrathecal injection of substance P1–7 amide produced prolongation of the tail-flick latency in both diabetic and non-diabetic mice, an effect that was more pronounced in diabetic mice than non-diabetic mice. Moreover, the observed antinociceptive potency of the substance P1–7 amide was higher in both diabetic and non-diabetic mice in comparison with the native substance P1–7. The antinociceptive effect of substance P1–7 amide was reversed by naloxone but not by the selective opioid receptor antagonist β-funaltrexamine, naltrindole or nor-binaltorphimine, selective for the μ-, δ- or κ-opioid receptor, respectively. In addition, the antinociceptive effect induced by substance P1–7 amide was partly reversed by the σ1 receptor agonist (+)-pentazocine, suggesting a possible involvement of the σ1 receptor for the action of this peptide. These results suggest that the actions of substance P1–7 amide mimic the effects of the native substance P fragment but with higher potency and that the mechanisms for its action may involve the σ1 receptor system. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice
- Author
-
Ohsawa, Masahiro, Aasato, Megumi, Hayashi, Shun-suke, and Kamei, Junzo
- Subjects
- *
PROTEIN kinases , *HYPERALGESIA , *DIABETIC neuropathies , *SPINAL cord , *WESTERN immunoblotting , *ALLODYNIA , *LABORATORY mice , *ENZYME inhibitors - Abstract
Abstract: Diabetic neuropathy is one of the most common complications of diabetes and causes various problems in daily life. Several investigations have noted that many factors in the spinal cord are involved in the symptoms of painful diabetic neuropathy, and there are very few effective therapeutic regimens. In the present study, we sought to elucidate the role of the RhoA/Rho kinase (ROCK) pathway in thermal hyperalgesia in diabetic mice. The intracellular localization of RhoA and the expression of eNOS were measured by western blotting. Thermal hyperalgesia was assessed by the tail-flick test and mechanical allodynia was assessed by automated von Frey filament test in streptozotocin(STZ)-induced diabetic mice. The spinal cord of STZ-treated diabetic mice showed increased membrane-bound RhoA compared to non-diabetic control. Treatment with the RhoA inhibitor exoenzyme C3, Clostridium botulinum, and the ROCK inhibitor Y27632 attenuated thermal hyperalgesia and mechanical allodynia in diabetic mice. Moreover, daily treatment with simvastatin attenuated all of those changes in diabetic mice. The expression of eNOS and NO metabolite contents in the spinal cord was decreased in diabetic mice, and these changes were normalized by treatment with simvastatin. The present results show that HMG-CoA reductase inhibitors have an inhibitory effect on thermal hyperalgesia in diabetic mice, which is mediated by an increase in NO production through the inhibition of RhoA/ROCK pathways. These results suggest that ROCK inhibitors and HMG-CoA inhibitors may be attractive compounds to relieve the symptoms of painful diabetic neuropathies. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
8. Effect of acute topical application of (+)-pentazocine on the mechanical allodynia in diabetic mice
- Author
-
Ohsawa, Masahiro, Hayashi, Shun-suke, and Kamei, Junzo
- Subjects
- *
PENTAZOCINE , *ALLODYNIA , *ANIMAL models of diabetes , *LABORATORY mice , *NOCICEPTORS , *DIABETES complications , *SIGMA receptors , *NITRIC oxide - Abstract
Abstract: Mechanical allodynia is a major complication in diabetic mellitus. Peripheral σ1 receptors were shown to be involved in nociceptive perception. We therefore investigated the effect of σ1 receptor ligand (+)-pentazocine injected into the dorsal surface of the hindpaw on mechanical allodynia in streptozotocin-induced diabetic mice. Injection of (+)-pentazocine (30μg) into the dorsal surface of the hindpaw did not affect the mechanical threshold and hindpaw NO contents in non-diabetic mice, whereas the mechanical allodynia and hindpaw contents of NO metabolites in diabetic mice were normalized by (+)-pentazocine. These effects of (+)-pentazocine in diabetic mice were inhibited by pretreatment with an σ receptor antagonist BD1047 into the same area, but not by systemic pretreatment with a κ-opioid receptor antagonist nor-binaltorphimine. These results suggest that (+)-pentazocine injected into the dorsal surface of the hindpaw increases the lowered mechanical threshold in diabetic mice through the activation of peripheral σ1 receptors. This attenuation may be, in part, due to the normalization of increased peripheral NO contents in the hindpaw of diabetic mice. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
9. Substance P1–7 induces antihyperalgesia in diabetic mice through a mechanism involving the naloxone-sensitive sigma receptors
- Author
-
Carlsson, Anna, Ohsawa, Masahiro, Hallberg, Mathias, Nyberg, Fred, and Kamei, Junzo
- Subjects
- *
HYPERALGESIA , *PEOPLE with diabetes , *LABORATORY mice , *NALOXONE , *SIGMA receptors , *TACHYKININ antagonists , *ANTI-inflammatory agents , *OPIOID receptors - Abstract
Abstract: We have recently explored the role of the tachykinin substance P neuroactive fragment substance P1–7 in the mediation of anti-inflammatory effects using a blister model in the rat paw (Wiktelius et al., 2006). We observed that this heptapeptide induced a dose-dependent inhibitory effect on the substance P-induced response, which was reversible by the non-selective opioid receptor antagonist naloxone. In the present study, we examined the ability of substance P1–7 to induce antihyperalgesic effects in streptozotocin-induced diabetic mice. We found that the substance P fragment strongly and dose-dependently produced antihyperalgesia in diabetic mice. This effect was reversed by naloxone but not by the selective opioid receptor antagonist β-funaltrexamine, naltrindole or nor-binaltorphimine, selective for the µ-, δ- or κ-opioid receptor, respectively. In addition, the antihyperalgesic effect induced by substance P1–7 was partly reversed by a σ1 receptor agonist (+)-pentazocine, but not a σ1 receptor antagonist BD1047 ([2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(diamino)ethylamine), suggesting that involvement of the naloxone-sensitive σ-receptor for the action of the SP related heptapeptides. These results suggest that hyperalgesia in diabetic mice may be, in part, due to the enhanced endogenous σ1 receptor systems in the spinal cord. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
10. Preventive effect of l-carnosine on changes in the thermal nociceptive threshold in streptozotocin-induced diabetic mice
- Author
-
Kamei, Junzo, Ohsawa, Masahiro, Miyata, Shigeo, and Tanaka, Shun-ichi
- Subjects
- *
CARNOSINE , *STREPTOZOTOCIN , *PREVENTIVE medicine , *DRUG administration , *PEOPLE with diabetes , *LABORATORY mice ,PREVENTION of diabetes complications - Abstract
Abstract: Sensory abnormality is one of the serious complications in diabetes. Since the effective therapeutic regimen to ameliorate the diabetic sensory abnormality is very few, the present study was then designed to investigate the effect of zinc l-carnosine on the changes of nociceptive threshold in diabetic mice. Zinc l-carnosine (75–300 mg/kg, p.o.) was administered once daily from 1 day after streptozotocin treatment. Diabetic mice showed shorter tail-flick latency at 1–4 weeks after streptozotocin treatment and longer tail-flick latency at 6–9 weeks after its treatment. The shortened tail-flick latency in early stage of diabetic mice was ameliorated by treatment with zinc l-carnosine. Moreover, zinc l-carnosine also slowed the onset of hypoalgesia in diabetic mice. Tail-flick latency in non-diabetic mice was not affected by the zinc l-carnosine treatment, indicating that zinc l-carnosine did not affect normal nociceptive transmission. Moreover, l-carnosine, but not zinc sulfate, ameliorated the abnormal sensory perception in diabetic mice. Interestingly, the ameliorative effect of zinc l-carnosine on the abnormal sensory perception in diabetic mice is much stronger than that of l-carnosine. These results provide the evidence of the ameliorative potential of zinc l-carnosine on the progressive diabetic neuropathy. Moreover, l-carnosine combined with zinc shows more potent amelioration of abnormal sensory perception in diabetic mice than by itself. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
11. Effects of cytidine 5′-diphosphocholine (CDP-choline) on the thermal nociceptive threshold in streptozotocin-induced diabetic mice
- Author
-
Kamei, Junzo, Ohsawa, Masahiro, Miyata, Shigeo, Endo, Kazuki, and Hayakawa, Hiroyuki
- Subjects
- *
NEUROPATHY , *CYTIDINE diphosphate choline , *DIABETES , *STREPTOZOTOCIN , *LABORATORY mice , *HYPERALGESIA , *SENSORY perception , *THERAPEUTICS - Abstract
Abstract: Neuropathy accompanied by abnormal sensory perception is the most common complication in insulin-dependent and -independent diabetes mellitus. Since there are very few effective therapeutic regimens for sensory abnormalities in diabetes, we examined the effect of cytidine 5′-diphosphocholine (CDP)-choline on the thermal nociceptive threshold in streptozotocin-induced diabetic mice using the tail-flick test. Diabetic mice showed a shorter tail-flick latency at 1–4 weeks after streptozotocin treatment and a longer tail-flick latency after 8–12 weeks. This hyper- and hypoalgesia in diabetic mice was almost completely inhibited by daily treatment with CDP-choline (100mg/kg/day, p.o.) beginning on the day of streptozotocin treatment. Daily treatment with CDP-choline beginning 5 weeks after streptozotocin treatment attenuated the development of hypoalgesia. Diabetic mice showed a significant increase in Na+-K+-ATPase activity at 3 weeks after streptozotocin treatment, whereas Na+-K+-ATPase activity was decreased at 12 weeks after treatment. These alterations were normalized by daily treatment with CDP-choline (100mg/kg/day, p.o.) beginning the day of streptozotocin treatment. These results provide evidence to support the therapeutic potency of CDP-choline on the development of thermal hyper- and hypoalgesia and the progression of thermal hypoalgesia in diabetic mice. Moreover, these effects of CDP-choline may result from the normalization of Na+-K+-ATPase activity. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
12. Response on: Chlorpheniramine exerts anxiolytic-like effects and activates prefrontal 5-HT systems in mice (Miyata S. et al., Psychopharmacology, 2009).
- Author
-
Ohsawa, Masahiro and Kamei, Junzo
- Subjects
- *
AMINES , *TRANQUILIZING drugs , *DRUG efficacy , *SEROTONIN uptake inhibitors , *PSYCHOPHARMACOLOGY , *LABORATORY mice , *DRUG receptors , *THERAPEUTICS - Published
- 2011
- Full Text
- View/download PDF
13. Involvement of the benzodiazepine system in the anxiolytic-like effect of Yokukansan (Yi-gan san)
- Author
-
Kamei, Junzo, Miyata, Shigeo, and Ohsawa, Masahiro
- Subjects
- *
BENZODIAZEPINE receptors , *TRANQUILIZING drugs , *DEMENTIA , *LABORATORY mice , *FLUMAZENIL , *ANALYSIS of variance , *ANXIETY , *PHYSIOLOGY ,JAPANESE herbal medicine - Abstract
Abstract: The traditional Japanese Kampo medicine Yokukansan (YKS, Yi-gan san in Chinese) has been demonstrated to improve the behavioral and psychological symptoms of dementia (BPSD), such as anxiety, hallucinations, agitation and irritability. The aim of this study was to elucidate the mechanism of the anxiolytic-like effects of YKS and Chotoko, which is an active component of YKS. Oral treatment with YKS (300 and 1000mg/kg) significantly increased the number of head-dipping behaviors in mice in the hole-board test. Head-dipping behavior in mice was also significantly increased by treatment with Chotoko (50 and 100mg/kg, p.o.). In addition, oral treatment with the water-extracted fractions from YKS (YKS-W; 250 and 500mg/kg, p.o.) and Chotoko (Chotoko-W; 10 and 30mg/kg) significantly increased the number of head-dipping behaviors in mice. On the other hand, treatment with the methanol-extracted fraction of YKS (YKS-Met; 15 and 30mg/kg, p.o.) did not affect head-dipping behavior. The total distance and number of rearing behaviors were not affected by treatment with any of these drugs. The increase in the number of head-dipping behaviors by treatment with YKS-W (500mg/kg, p.o.) and Chotoko-W (30mg/kg, p.o.) was inhibited by pretreatment with the benzodiazepine receptor antagonist flumazenil (1mg/kg, i.v.). In the elevated plus-maze test, the percentage of time spent in open arms was increased in YKS (1000mg, p.o.) treatment. Based on these results, we suggest that YKS produces an anxiolytic-like effect mediated by the benzodiazepine system. Chotoko is an effective component of YKS for producing an anxiolytic-like effect. The effective compound(s) should be contained, at least in part, in the water-soluble fraction of YKS. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
14. Olanzapine induces glucose intolerance through the activation of AMPK in the mouse hypothalamus.
- Author
-
Ikegami, Megumi, Ikeda, Hiroko, Ishikawa, Yoko, Ohsawa, Masahiro, Ohashi, Takahiro, Kai, Misa, Kamei, Atsuko, and Kamei, Junzo
- Subjects
- *
OLANZAPINE , *GLUCOSE intolerance , *CYCLIC-AMP-dependent protein kinase , *HYPOTHALAMUS , *HOMEOSTASIS , *LABORATORY mice - Abstract
Abstract: Treatment with atypical antipsychotic drugs is known to increase the risk of glucose intolerance and diabetes. However, the mechanism of this effect is unclear. Since central adenosine 5?-monophosphate-activated protein kinase (AMPK) plays an important role in regulating nutrient homeostasis, the present study was performed to examine the involvement of central AMPK in the glucose intolerance induced by olanzapine, an atypical antipsychotic drug, in mice. Acute intraperitoneal treatment with olanzapine dose-dependently increased blood glucose levels in the glucose tolerance test. Intracerebroventricular administration of olanzapine also increased blood glucose levels in the glucose tolerance test. The glucose intolerance induced by both intraperitoneal and intracerebroventricular treatment with olanzapine was significantly attenuated by intracerebroventricular pretreatment with the AMPK inhibitor compound C. Intracerebroventricular treatment with the AMPK activator AICAR increased blood glucose levels in the glucose tolerance test, and this increase was inhibited by compound C. Moreover, the hypothalamic level of phosphorylated AMPK after glucose injection was significantly increased by intracerebroventricular pretreatment with olanzapine. Olanzapine did not affect plasma glucagon and insulin levels. Our results indicate that acute treatment with olanzapine causes glucose intolerance through the activation of hypothalamic AMPK. The present study suggests that the inhibition of central AMPK activity may have a therapeutic effect on the metabolic disturbance induced by atypical antipsychotic drugs. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
15. Possible involvement of tetrodotoxin-resistant sodium channels in cough reflex
- Author
-
Kamei, Junzo, Nakanishi, Yuki, Ishikawa, Yoko, Hayashi, Shun-suke, Asato, Megumi, and Ohsawa, Masahiro
- Subjects
- *
TETRODOTOXIN , *SODIUM channels , *COUGH , *ANTITUSSIVE agents , *CITRIC acid , *LABORATORY mice - Abstract
Abstract: We examined the involvement of tetrodotoxin (TTX)-resistant sodium channels in the peripheral mechanisms of the cough reflex in mice. We also examined the possibility of using ambroxol as an effective antitussive agent, and found that it produced antitussive effects through the inhibition of TTX-resistant sodium channels. The inhalation of fenvalerate, at concentrations of 0.3, 1 and 3μg/ml, for 5min produced coughs in a concentration-dependent manner. Pretreatment with tetrodotoxin, at a dose of 1μg/kg, s.c., slightly but significantly reduced the number of fenvalerate (3μg/ml)-induced coughs. However, the number of fenvalerate-induced coughs in tetorodotoxin-treated mice was still significantly greater than those in vehicle (0.4% DMSO) alone inhaled mice. On the other hand, pretreatment with tetrodotoxin, at a dose of 1μg/kg, s.c., almost completely reduced the number of citric acid (0.25M)-induced coughs to the level in vehicle (saline) alone inhaled mice. Pretreatment with ambroxol, at doses of 10, 30, 100 and 300mg/kg, p.o., dose-dependently and significantly reduced the number of fenvalerate (3μg/ml)-induced coughs. The present findings indicate that TTX-resistant sodium channels may play an important role in the enhancement of C-fiber-mediated cough pathways. Furthermore, ambroxol may prove to be a useful cough suppressant. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.